In the treatment of non-metastatic insulinomas, which of the following statements regarding octreotide and/or lanreotide are correct?
Randomized data showed an improvement in progression free survival with lanreotide vs. placebo.
In the absence of insulinoma somatostatin receptors, octreotide or lanreotide can profoundly worsen hypoglycemia.
Octreotide is more easily administered than lanreotide.
Lanreotide is significantly more effective than octreotide in decreasing excess tumor hormone production.
Vote
View Results